Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients

Virology Journal

Volumn 7, Issue , 2010, Pages

  Cao, Zhiliang ^a   Liu, Lifeng ^b   Du, Lanying ^c   Zhang, Chao ^a   Jiang, Shibo ^c   Li, Taisheng ^b   He, Yuxian ^a  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS SPIKE PROTEIN; MEMBRANE PROTEIN; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; ARTICLE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOGENICITY; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; ANIMAL; BLOOD; FOLLOW UP; IMMUNOLOGY; PROTEIN TERTIARY STRUCTURE; SERODIAGNOSIS; TIME;

ANIMALIA; SARS CORONAVIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HUMANS; MEMBRANE GLYCOPROTEINS; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TIME FACTORS; VIRAL ENVELOPE PROTEINS;

EID: 78049374354     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-299     Document Type: Article

References (36)

1. Bats are natural reservoirs of SARS-like coronaviruses. W Li Z Shi M Yu W Ren C Smith JH Epstein H Wang G Crameri Z Hu H Zhang,, et al. Science 2005 310 676 679 10.1126/science.1118391 16195424
2. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. PA Rota MS Oberste SS Monroe WA Nix R Campagnoli JP Icenogle S Penaranda B Bankamp K Maher MH Chen,, et al. Science 2003 300 1394 1399 10.1126/science.1085952 12730500
3. The Genome sequence of the SARS-associated coronavirus. MA Marra SJ Jones CR Astell RA Holt A Brooks-Wilson YS Butterfield J Khattra JK Asano SA Barber SY Chan,, et al. Science 2003 300 1399 1404 10.1126/science.1085953 12730501
4. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. S Liu G Xiao Y Chen Y He J Niu CR Escalante H Xiong J Farmar AK Debnath P Tien S Jiang, Lancet 2004 363 938 947 10.1016/S0140-6736(04)15788-7 15043961
5. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. BJ Bosch BE Martina R Van Der Zee J Lepault BJ Haijema C Versluis AJ Heck R De Groot AD Osterhaus PJ Rottier, Proc Natl Acad Sci USA 2004 101 8455 8460 10.1073/pnas.0400576101 15150417
6. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. G Simmons JD Reeves AJ Rennekamp SM Amberg AJ Piefer P Bates, Proc Natl Acad Sci USA 2004 101 4240 4245 10.1073/pnas.0306446101 15010527
7. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. UJ Buchholz A Bukreyev L Yang EW Lamirande BR Murphy K Subbarao PL Collins, Proc Natl Acad Sci USA 2004 101 9804 9809 10.1073/pnas.0403492101 15210961 (Pubitemid 38869317)
8. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. ZY Yang WP Kong Y Huang A Roberts BR Murphy K Subbarao GJ Nabel, Nature 2004 428 561 564 10.1038/nature02463 15024391
9. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. H Bisht A Roberts L Vogel A Bukreyev PL Collins BR Murphy K Subbarao B Moss, Proc Natl Acad Sci USA 2004 101 6641 6646 10.1073/pnas.0401939101 15096611
10. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. A Bukreyev EW Lamirande UJ Buchholz LN Vogel WR Elkins M St Claire BR Murphy K Subbarao PL Collins, Lancet 2004 363 2122 2127 10.1016/S0140-6736(04)16501-X 15220033
11. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. J ter Meulen AB Bakker EN van den Brink GJ Weverling BE Martina BL Haagmans T Kuiken J de Kruif W Preiser W Spaan,, et al. Lancet 2004 363 2139 2141 10.1016/S0140-6736(04)16506-9 15220038
12. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. Y He Y Zhou H Wu B Luo J Chen W Li S Jiang, J Immunol 2004 173 4050 4057 15356154
13. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. SK Wong W Li MJ Moore H Choe M Farzan, J Biol Chem 2004 279 3197 3201 10.1074/jbc.C300520200 14670965
14. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. GJ Babcock DJ Esshaki WD Thomas Jr DM Ambrosino, J Virol 2004 78 4552 4560 10.1128/JVI.78.9.4552-4560.2004 15078936
15. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. W Li MJ Moore N Vasilieva J Sui SK Wong MA Berne M Somasundaran JL Sullivan K Luzuriaga TC Greenough,, et al. Nature 2003 426 450 454 10.1038/nature02145 14647384
16. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. Y He H Lu P Siddiqui Y Zhou S Jiang, J Immunol 2005 174 4908 4915 15814718
17. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. Y He J Li W Li S Lustigman M Farzan S Jiang, J Immunol 2006 176 6085 6092 16670317
18. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. Y He J Li S Heck S Lustigman S Jiang, J Virol 2006 80 5757 5767 10.1128/JVI.00083-06 16731915
19. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Y He Q Zhu S Liu Y Zhou B Yang J Li S Jiang, Virology 2005 334 74 82 10.1016/j.virol.2005.01.034 15749124
20. The spike protein of SARS-CoV - a target for vaccine and therapeutic development. L Du Y He Y Zhou S Liu BJ Zheng S Jiang, Nat Rev Microbiol 2009 7 226 236 10.1038/nrmicro2090 19198616
21. Vaccine design for severe acute respiratory syndrome coronavirus. Y He S Jiang, Viral Immunol 2005 18 327 332 10.1089/vim.2005.18.327 16035944
22. SARS vaccine development. S Jiang Y He S Liu, Emerg Infect Dis 2005 11 1016 1020 16022774
23. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. L Du G Zhao CC Chan S Sun M Chen Z Liu H Guo Y He Y Zhou BJ Zheng S Jiang, Virology 2009 393 144 150 10.1016/j.virol.2009.07.018 19683779
24. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. L Du G Zhao Y He Y Guo BJ Zheng S Jiang Y Zhou, Vaccine 2007 25 2832 2838 10.1016/j.vaccine.2006.10.031 17092615
25. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. L Du G Zhao Y Lin H Sui C Chan S Ma Y He S Jiang C Wu KY Yuen,, et al. J Immunol 2008 180 948 956 18178835
26. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Z Zhu S Chakraborti Y He A Roberts T Sheahan X Xiao LE Hensley P Prabakaran B Rockx IA Sidorov,, et al. Proc Natl Acad Sci USA 2007 104 12123 12128 10.1073/pnas.0701000104 17620608
27. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. J Sui W Li A Murakami A Tamin LJ Matthews SK Wong MJ Moore AS Tallarico M Olurinde H Choe,, et al. Proc Natl Acad Sci USA 2004 101 2536 2541 10.1073/pnas.0307140101 14983044
28. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Y He J Li L Du X Yan G Hu Y Zhou S Jiang, Vaccine 2006 24 5498 5508 10.1016/j.vaccine.2006.04.054 16725238
29. A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. Y He J Li S Jiang, Biochem Biophys Res Commun 2006 344 106 113 10.1016/j.bbrc.2006.03.139 16615996
30. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Y He Y Zhou S Liu Z Kou W Li M Farzan S Jiang, Biochem Biophys Res Commun 2004 324 773 781 10.1016/j.bbrc.2004.09.106 15474494
31. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Y He Y Zhou P Siddiqui S Jiang, Biochem Biophys Res Commun 2004 325 445 452 10.1016/j.bbrc.2004.10.052 15530413
32. Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. Y He Y Zhou P Siddiqui J Niu S Jiang, J Clin Microbiol 2005 43 3718 3726 10.1128/JCM.43.8.3718-3726. 2005 16081901 (Pubitemid 41129651)
33. Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus. Y He Y Zhou H Wu Z Kou S Liu S Jiang, J Clin Microbiol 2004 42 5309 5314 10.1128/JCM.42.11.5309-5314.2004 15528730
34. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. L Du G Zhao Y Lin C Chan Y He S Jiang C Wu DY Jin KY Yuen Y Zhou BJ Zheng, Vaccine 2008 26 1644 1651 10.1016/j.vaccine. 2008.01.025 18289745
35. Duration of antibody responses after severe acute respiratory syndrome. LP Wu NC Wang YH Chang XY Tian DY Na LY Zhang L Zheng T Lan LF Wang GD Liang, Emerg Infect Dis 2007 13 1562 1564 18258008
36. Disappearance of antibodies to SARS-associated coronavirus after recovery. WC Cao W Liu PH Zhang F Zhang JH Richardus, N Engl J Med 2007 357 1162 1163 10.1056/NEJMc070348 17855683